Floatz logo

Toripalimab

ALK-Positive Anaplastic Large Cell Lymphoma

Huiqiang Huangmonoclonal_antibodyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the ALK-Positive Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Mingzhi Zhang
Phase 4BB
Crizotinib
Mingzhi Zhang
Phase 4BB
Inno-206
Huiqiang Huang
Phase 2BB
DEXAMETHASONE
Huiqiang Huang
Phase 2BB
Cyclophosphamide
Huiqiang Huang
Phase 2BB

View all 33 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →